MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317580 | Name: Dantrolene
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dantrolene sodium is a postsynaptic muscle relaxant that lessens excitation-contraction coupling in muscle cells. It achieves this by inhibiting Ca2+ ions release from sarcoplasmic reticulum stores by antagonizing ryanodine receptors. It is the primary drug used for the treatment and prevention of malignant hyperthermia, a rare, life-threatening disorder triggered by general anesthesia. It is also used in the management of neuroleptic malignant syndrome, muscle spasticity (e.g. after strokes, in paraplegia, cerebral palsy, or patients with multiple sclerosis), and 2,4-dinitrophenol poisoning.

Chemical Structure

Dantrolene
Dantrolene
CAS#7261-97-4 (free)

Theoretical Analysis

MedKoo Cat#: 317580

Name: Dantrolene

CAS#: 7261-97-4 (free)

Chemical Formula: C14H10N4O5

Exact Mass: 314.0651

Molecular Weight: 314.25

Elemental Analysis: C, 53.51; H, 3.21; N, 17.83; O, 25.46

Price and Availability

Size Price Availability Quantity
100mg USD 250.00 2 Weeks
250mg USD 450.00 2 Weeks
1g USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
7261-97-4 (free) 24868-20-0 (sodium hydrate) 14663-23-1 (sodium)
Synonym
Dantrolene; Dantroleno; Dantrolenum; Dantrium; Dantrolenum; F 368; F368; F-368
IUPAC/Chemical Name
1-[[[5-(4-Nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolinedione
InChi Key
OZOMQRBLCMDCEG-VIZOYTHASA-N
InChi Code
InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+
SMILES Code
C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Certificate of Analysis
View CoA: current batch, Lot#T20R06C30
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 314.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Britt BA. Dantrolene. Can Anaesth Soc J. 1984 Jan;31(1):61-75. doi: 10.1007/BF03011484. PMID: 6362802. 2: Campos Suárez JM, Escolano Villén F, Catalá Puigbó E, Villar Landeira JM, Sanz Mazó M. Dantroleno sódico [Sodium dantrolene]. Rev Esp Anestesiol Reanim. 1985 Jul-Aug;32(4):179-83. Spanish. PMID: 3901158. 3: Farkhondeh T, Roshanravan B, Shirazi FM, Mehrpour O. Can dantrolene be used in the treatment of cardioglycosides poisonings? Expert Opin Drug Metab Toxicol. 2021 Jan;17(1):1-2. doi: 10.1080/17425255.2021.1843632. Epub 2020 Nov 10. PMID: 33111579. 4: Alkazmi L, Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, Ahmed EA, Batiha GE. Dantrolene and ryanodine receptors in COVID-19: The daunting task and neglected warden. Clin Exp Pharmacol Physiol. 2023 May;50(5):335-352. doi: 10.1111/1440-1681.13756. Epub 2023 Feb 28. PMID: 36732880. 5: Liang L, Wei H. Dantrolene, a treatment for Alzheimer disease? Alzheimer Dis Assoc Disord. 2015 Jan-Mar;29(1):1-5. doi: 10.1097/WAD.0000000000000076. PMID: 25551862; PMCID: PMC4334699. 6: Abou MB, Sun L, Wei H. Approaches to Optimizing Dantrolene Neuroprotection for the Treatment of Alzheimer's Disease. Curr Alzheimer Res. 2020;17(4):324-328. doi: 10.2174/1567205017666200522204722. PMID: 32442084; PMCID: PMC7705762. 7: Russell T, Steel A. Dantrolene preparation. Anaesth Intensive Care. 2011 Nov;39(6):1150; author reply 1150-1. PMID: 22165375. 8: Nawata T, Sakai H, Honda T, Otsuka M, Fujita H, Uchinoumi H, Kobayashi S, Yamamoto T, Asagiri M, Yano M. Dantrolene, a stabilizer of the ryanodine receptor, prevents collagen-induced arthritis. Biochem Biophys Res Commun. 2022 Oct 8;624:141-145. doi: 10.1016/j.bbrc.2022.07.111. Epub 2022 Aug 2. PMID: 35940127. 9: Ward A, Chaffman MO, Sorkin EM. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs. 1986 Aug;32(2):130-68. doi: 10.2165/00003495-198632020-00003. PMID: 3527659. 10: Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73. doi: 10.1111/j.1365-2044.2004.03658.x. PMID: 15023108. 11: Pinder RM, Brogden RN, Speight TM, Avery GS. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs. 1977 Jan;13(1):3-23. doi: 10.2165/00003495-197713010-00002. PMID: 318989. 12: Gerbershagen MU, Fiege M, Krause T, Agarwal K, Wappler F. Dantrolen. Pharmakologische und therapeutische Aspekte [Dantrolene. Pharmacological and therapeutic aspects]. Anaesthesist. 2003 Mar;52(3):238-45. German. doi: 10.1007/s00101-003-0461-7. PMID: 12666006. 13: Allen GC. Oral dantrolene. Anaesthesia. 2004 Nov;59(11):1139; author reply 1139-40. doi: 10.1111/j.1365-2044.2004.03979.x. PMID: 15479327. 14: Schneider R, Mitchell D. Dantrolene hepatitis. JAMA. 1976 Apr 12;235(15):1590-1. PMID: 946274. 15: Muehlschlegel S, Sims JR. Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit. Neurocrit Care. 2009;10(1):103-15. doi: 10.1007/s12028-008-9133-4. Epub 2008 Aug 12. PMID: 18696266; PMCID: PMC2702250. 16: Samiotis I, Papakonstantinou NA, Dedeilias P, Vasileiadis I, Papalois A, Deftereos S, Kotanidou A. Dantrolene Induces Mitigation of Myocardial Ischemia- Reperfusion Injury by Ryanodine Receptor Inhibition. Semin Thorac Cardiovasc Surg. 2022 Spring;34(1):123-132. doi: 10.1053/j.semtcvs.2021.01.004. Epub 2021 Jan 15. PMID: 33460764. 17: Dantrolene sodium (Dantrium). Drug Ther Bull. 1976 Jul 30;14(16):61-3. PMID: 964132. 18: Harrison GG. Malignant hyperthermia. Dantrolene--dynamics and kinetics. Br J Anaesth. 1988 Feb;60(3):279-86. doi: 10.1093/bja/60.3.279. PMID: 3279988. 19: Hetherington N. Dantrolene. Aust Nurses J. 1992 Mar;21(8):28-9. PMID: 1605782. 20: Hopkins S. Pharmacology: dantrolene sodium. Nurs Mirror. 1980 Dec 11;151(24):30. PMID: 6905140.